NASDAQ:TGTX
TG Therapeutics Stock News
$16.55
-0.210 (-1.25%)
At Close: Jun 14, 2024
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call Transcript
05:38pm, Tuesday, 01'st Mar 2022 Seeking AlphaTG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
01:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call Transcript
12:38pm, Tuesday, 01'st Mar 2022
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call Transcript
TG Therapeutics GAAP EPS of -$0.70 misses by $0.08, revenue of $2.32M beats by $0.08M
12:35pm, Tuesday, 01'st Mar 2022 Seeking Alpha
TG Therapeutics press release (TGTX): Q4 GAAP EPS of -$0.70 misses by $0.08.Revenue of $2.32M (+5700.0% Y/Y) beats by $0.08M.
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
12:30pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
12:30pm, Tuesday, 01'st Mar 2022 GlobeNewswire
Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
09:58am, Tuesday, 01'st Mar 2022
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics Q4 2021 Earnings Preview
05:12pm, Monday, 28'th Feb 2022 Seeking Alpha
TG Therapeutics (NASDAQ:TGTX) is scheduled to announce Q4 esults on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.68 and consensus revenue estimate is $2.4M
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACT
AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates
01:05pm, Thursday, 24'th Feb 2022 Zacks Investment Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
07:30am, Thursday, 24'th Feb 2022
Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials eva
Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe
09:33pm, Monday, 07'th Feb 2022
TGTX is trading like a junk stock after the FDA announced that it is investigating umbralisib in CLL over safety concerns. However, people tend to forget, ublituximab for MS is the heart of TGTX.
TG Therapeutics slips on concerns over FDA probe on cancer medicine
03:22pm, Thursday, 03'rd Feb 2022 Seeking Alpha
TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine
TG Therapeutics (TGTX) Moves 17.7% Higher: Will This Strength Last?
07:04am, Monday, 31'st Jan 2022 Zacks Investment Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.